Molecular Partners Presented Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial Of MP0533 For Patients With Relapsed/Refractory AML And AML/MDS At 2023 ASH Meeting

Author: Charles Gross | December 10, 2023 01:51pm

Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today presented positive initial clinical data from its ongoing Phase 1/2a trial of MP0533, a novel tetra-specific T cell engager, in a poster at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. These data, which highlight encouraging initial safety and antitumor activity, expand upon those previously disclosed in the conference abstract.

• Initial antitumor activity observed in early MP0533 dose-escalation cohorts, with a previously undisclosed complete response (CR) observed in dose range four, in addition to the previously reported responder in dose range three
   
• MP0533 monotherapy continues to demonstrate an acceptable safety profile across the first four dosing cohorts, with no dose-limiting toxicities observed
   
• Phase 1/2a trial remains ongoing with patients being enrolled in fifth of seven planned dose-escalation cohorts

Posted In: MOLN